De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

TransCode Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO TransCode Therapeutics' is Tom Fitzgerald, benoemd in Jul2018, heeft een ambtstermijn van 6.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 426.86K, bestaande uit 83.9% salaris en 16.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.008% van de aandelen van het bedrijf, ter waarde $ 803.48. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.3 jaar en 6 jaar.

Belangrijke informatie

Tom Fitzgerald

Algemeen directeur

US$426.9k

Totale compensatie

Percentage CEO-salaris	83.9%
Dienstverband CEO	6.3yrs
Eigendom CEO	0.008%
Management gemiddelde ambtstermijn	6.3yrs
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

TransCode Therapeutics reports Q2 results

Aug 15

TransCode files U.S. patent application for radiotherapy based cancer treatment

Jul 11

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Apr 01

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Dec 15

Analyse CEO-vergoeding

Hoe is Tom Fitzgerald's beloning veranderd ten opzichte van TransCode Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	n/a	n/a	-US$17m
Dec 31 2023	US$427k	US$358k	-US$19m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$561k	US$371k	-US$18m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$318k	US$180k	-US$7m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$4m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	US$15k	n/a	-US$2m

Compensatie versus markt: De totale vergoeding ($USD 426.86K ) Tom } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Tom is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Tom Fitzgerald (72 yo)

6.3yrs

Tenure

US$426,862

Compensatie

Mr. Thomas A. Fitzgerald, also known as Tom, M.B.A. has been the Director of TransCode Therapeutics Inc. since July 2018. He serves as Chief Financial Officer at TransCode Therapeutics, Inc. since July 201...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Philippe Calais	Executive Chairman of the Board	6yrs	US$112.61k	0.00093% $ 98.4
Thomas Fitzgerald	Interim CEO	6.3yrs	US$426.86k	0.0081% $ 862.6
Zdravka Medarova	Co-Founder & Chief Scientific Officer	8.8yrs	geen gegevens	0% $ 0
Anna Moore	Co-Founder	8.8yrs	geen gegevens	0% $ 0
Susan Duggan	Senior Vice President of Operations	no data	geen gegevens	geen gegevens
Daniel Vlock	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RNAZ is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Philippe Calais	Executive Chairman of the Board	6yrs	US$112.61k	0.00093% $ 98.4
Thomas Fitzgerald	Interim CEO	6.3yrs	US$426.86k	0.0081% $ 862.6
Anna Moore	Co-Founder	8.8yrs	geen gegevens	0% $ 0
John Henneman	Member of Advisory Board	no data	geen gegevens	geen gegevens
G. Srivatsa	Member of Advisory Board	no data	geen gegevens	geen gegevens
Magda Marquet	Independent Director	3.8yrs	US$75.11k	0% $ 0
Dmitry Samarsky	Member of Advisory Board	no data	geen gegevens	geen gegevens
Keith Flaherty	Member of Advisory Board	no data	geen gegevens	geen gegevens
Raul Mostoslavsky	Member of Advisory Board	no data	geen gegevens	geen gegevens
George Calin	Member of Advisory Board	no data	geen gegevens	geen gegevens
Raghu Kalluri	Member of Advisory Board	no data	geen gegevens	geen gegevens
Erik Manting	Independent Director	3.8yrs	US$73.11k	0% $ 0

6.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RNAZ wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

TransCode Therapeutics Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

Co-Founder recently bought US$55k worth of stock

Recent updates

TransCode Therapeutics, Inc. Receives Non-Compliance Letter from Staff of Nasdaq

TransCode Therapeutics, Inc. Announces First Patients Treated in Phase 1 Clinical Trial with First-In-Class Lead Therapeutic Candidate

TransCode Therapeutics Receives Deficiency Letters from the Listing Qualifications Department (The “Staff”) of the Nasdaq

TransCode Therapeutics, Inc. Announces Phase 1 Clinical Trial Initiation

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $3 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Intends to File a Request for a Hearing on or before May 14, 2024, in Response to Non-Compliance with the Nasdaq Listing Rule 5550(a)(2)

TransCode Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

TransCode Therapeutics, Inc. Announces Fda Clearance to Initiate Phase 1/2 Clinical Trial Withttx-Mc138 in Patients with Advanced Solid Tumors

TransCode Therapeutics, Inc. Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist Immunotherapeutic

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.194863 million.

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.25 million.

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. Announces CEO Changes

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering.

TransCode Therapeutics, Inc. Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with Its Lead Candidate, TTX-MC138

TransCode Therapeutics, Inc. to Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.21 million.

TransCode Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Required for Continued Listing on The Nasdaq Capital Market

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on the Nasdaq Stock Market Subject to Conditions

Transcode Therapeutics, Inc. Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Leading Therapeutic Candidate, Tx-Mc138

TransCode Therapeutics, Inc. Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate,TTX-MC138

TransCode Therapeutics, Inc. Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

TransCode Therapeutics Provides Non Compliance Update

TransCode Therapeutics Receives Delisting Determination Letter from Nasdaq Advising Not to Accept its Compliance Plan, and Denies its Request for an Extension

TransCode Therapeutics, Inc. Announces Publication of New Data Supporting Use of TTX-MC138 for Treatment of Metastatic Breast Cancer

New major risk - Shareholder dilution

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Lead Candidate, Tx-MC138, in Glioblastoma

TransCode Therapeutics Announces 1-For-20 Reverse Stock Split to Satisfy the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

TransCode Therapeutics Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma

Transcode Therapeutics, Inc. Announces FDA Authorization to Proceed with First-In-Human Clinical Trial

Transcode Therapeutics Announces Eind Submission to Us Fda for Planned First-In-Human Clinical Trial in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-siPDL1, in Pancreatic Adenocarcinoma

TransCode Therapeutics, Inc. Reports Positive Preclinical Results with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Publication of Feline Case Study in Frontiers in Oncology

TransCode Therapeutics, Inc. Appoints Frank J. Slack to its Advisory Board

TransCode Therapeutics reports Q2 results

TransCode files U.S. patent application for radiotherapy based cancer treatment

Co-Founder recently bought US$55k worth of stock

TransCode Therapeutics, Inc. Acquires Option for Radiotheranostic Technology

TransCode Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

TransCode Therapeutics, Inc. Announces Publication in Cancer Nanotechnology of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Metastatic Breast Cancer

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd